Holen Sie sich die Stockscreener-App
2.7377
2.24%
0.0577
Schlusskurs vom Vortag:
$2.68
Offen:
$2.75
24-Stunden-Volumen:
80,085
Relative Volume:
0.12
Marktkapitalisierung:
$152.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-3.2592
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
-8.67%
1M Leistung:
-29.02%
6M Leistung:
+60.23%
1J Leistung:
+45.74%
1-Tages-Spanne:
$2.69
$2.815
1-Wochen-Bereich:
$2.67
$3.09
52-Wochen-Spanne:
$0.7203
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Vergleichen Sie QNCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
2.74 | 149.23M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Can Quince Therapeutics Inc. stock beat market expectations this quarterFit and Size Notes & lightweight options for faster days - ulpravda.ru
Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com - Investing.com India
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com
Can Quince Therapeutics Inc. stock sustain institutional interestJuly 2025 Rallies & Daily Volume Surge Signals - ulpravda.ru
Returns Recap: How Quince Therapeutics Inc. stock compares to industry benchmarksTrade Risk Assessment & Risk Managed Investment Entry Signals - ulpravda.ru
Quince Therapeutics reports Q3 EPS (25c), consensus (22c) - MSN
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Growth in Short Interest - MarketBeat
Insider Sell: Luca Benatti Sells 50,000 Shares of Quince Therape - GuruFocus
QNCX Insider Trading - Quiver Quantitative
Aug Mood: Is Quince Therapeutics Inc. stock a safe buy before earnings2025 Performance Recap & Expert Curated Trade Ideas - Улправда
Quince Therapeutics Earnings Notes - Trefis
Will Quince Therapeutics Inc. stock outperform value stocks2025 Performance Recap & High Return Trade Opportunity Guides - Улправда
Insider Trends: Is Quince Therapeutics Inc. stock a safe buy before earningsJuly 2025 Decliners & Technical Buy Zone Confirmations - Улправда
Why Quince Therapeutics Inc. stock is considered a top pick2025 Technical Overview & Reliable Volume Spike Trade Alerts - DonanımHaber
Technical Analysis: Will Quince Therapeutics Inc. stock outperform value stocksMarket Activity Report & AI Enhanced Trading Alerts - ulpravda.ru
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital - Yahoo Finance
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - BioSpace
Quince Therapeutics Inc (QNCX) deserves deeper analysis - uspostnews.com
D. Boral Capital Maintains Quince Therapeutics (QNCX) Buy Recommendation - Nasdaq
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Quince Therapeutics (NASDAQ:QNCX) Price Target Raised to $5.00 at D. Boral Capital - MarketBeat
Quince marks final patient visit in NEAT phase 3 study - marketscreener.com
Quince Marks Final Patient Visit in NEAT Phase 3 Study - TradingView — Track All Markets
Quince Therapeutics (QNCX) Concludes Phase 3 Trial for Key Drug - GuruFocus
Quince Therapeutics (QNCX) CEO moves 739,885 common shares to Thye Trust - Stock Titan
Quince Therapeutics publishes early-stage data on eDSP drug delivery system - Investing.com Nigeria
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - BioSpace
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonar - pharmiweb.com
Quince Therapeutics (QNCX) Publishes Promising Early Clinical Study Results - GuruFocus
Quince Therapeutics (QNCX) Publishes Promising Early Clinical St - GuruFocus
QNCX (Quince Therapeutics Inc) has impressive results - uspostnews.com
Check out these key findings about Quince Therapeutics Inc (QNCX) - setenews.com
COO Hannah Acquires 27,551 Of Quince Therapeutics Inc [QNCX] - TradingView — Track All Markets
Trading Action: Is Quince Therapeutics Inc stock a safe buy before earnings2025 Price Momentum & Accurate Trade Setup Notifications - moha.gov.vn
Quince Therapeutics, Inc. (QNCX) -11.5% in After-hours: No Clear Catalyst Driving Decline - Stocks Telegraph
Quince Therapeutics, Inc. (QNCX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why Quince Therapeutics Inc. stock is trending among retail traders2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
Why Quince Therapeutics Inc. stock remains resilientWeekly Investment Recap & Weekly Top Stock Performers List - Newser
Quince Therapeutics (QNCX) Stock Analysis Report | Financials & Insights - Benzinga
Prepare Yourself for Liftoff: Quince Therapeutics Inc (QNCX) - Setenews
169,554 Shares in Quince Therapeutics, Inc. $QNCX Bought by Rockefeller Capital Management L.P. - MarketBeat
Quince Therapeutics Stock Surges 105%, With A 8-Day Winning Spree - Trefis
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Consensus Target Price from Analysts - Defense World
Quince Therapeutics, Inc. (QNCX) 18.8% in Intraday Trading: Surge Amid Upcoming Investor Events - Stocks Telegraph
Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis
Quince Therapeutics: Could NEAT Phase 3 Data Deliver The First Therapy For Ataxia-Telangiectasia? - RTTNews
Adversity is less terrifying than hope: Quince Therapeutics Inc (QNCX) - Setenews
EBITDA per share of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics to Participate at Investor Events in December 2025 - Markets Financial Content
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quince Therapeutics Inc-Aktie (QNCX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):